Literature DB >> 22169381

Hemolysis upon intravenous immunoglobulin transfusion.

Ruth F Padmore1.   

Abstract

Intravenous immunoglobulin (IVIG) is a mainstay of therapy in many disorders. An uncommon adverse side effect is IVIG-related hemolysis. Risk factors for IVIG-related hemolysis have been identified, including high dose IVIG given to non-O blood group recipients with an underlying inflammatory state. IVIG-related hemolysis has been linked to anti-A and anti-B hemagglutinins in the IVIG preparations and may involve both IgG and complement mediated hemolysis. A two-hit mechanism with threshold effect is proposed for IVIG-related hemolysis. Strategies exist to minimize or avoid IVIG-related hemolysis. Copyright Â
© 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22169381     DOI： 10.1016/j.transci.2011.11.004

Source DB:  PubMed          Journal:  Transfus Apher Sci        ISSN： 1473-0502            Impact factor:   1.764


  9 in total

1.  American Society of Nephrology Quiz and Questionnaire 2013: transplantation.

Authors:  Michelle A Josephson; Mark A Perazella; Michael J Choi
Journal:  Clin J Am Soc Nephrol       Date:  2014-04-17       Impact factor: 8.237

2.  ABO-Incompatible Living Donor Liver Transplantation in Focus of Antibody Rebound.

Authors:  Silke Rummler; Astrid Bauschke; Erik Baerthel; Heike Juette; Katrin Maier; Christina Malessa; Dagmar Barz; Utz Settmacher
Journal:  Transfus Med Hemother       Date:  2016-11-09       Impact factor: 3.747

3.  Treatment-associated hemolysis in Kawasaki disease: association with blood-group antibody titers in IVIG products.

Authors:  Christine W Bruggeman; Sietse Q Nagelkerke; Wendy Lau; Cedric Manlhiot; Masja de Haas; Robin van Bruggen; Brian W McCrindle; Rae S M Yeung; Taco W Kuijpers
Journal:  Blood Adv       Date:  2020-07-28

4.  Isoagglutinin Reduction in Human Immunoglobulin Products by Donor Screening.

Authors:  Brigitte Siani; Katharina Willimann; Sandra Wymann; Adriano A Marques; Eleonora Widmer
Journal:  Biol Ther       Date:  2014-05-20

Review 5.  On the dark side of therapies with immunoglobulin concentrates: the adverse events.

Authors:  Peter J Späth; Guido Granata; Fabiola La Marra; Taco W Kuijpers; Isabella Quinti
Journal:  Front Immunol       Date:  2015-02-05       Impact factor: 7.561

6.  Reduction of Isoagglutinin in Intravenous Immunoglobulin (IVIG) Using Blood Group A- and B-Specific Immunoaffinity Chromatography: Industry-Scale Assessment.

Authors:  Simon Gerber; Annette Gaida; Nicole Spiegl; Sandra Wymann; Adriano Marques Antunes; Ibrahim El Menyawi; Brigitte Zurbriggen; Alphonse Hubsch; Martin Imboden
Journal:  BioDrugs       Date:  2016-10       Impact factor: 5.807

Review 7.  Dentoalveolar Procedures in Immune Thrombocytopenia; Systematic Review and an Institutional Guideline.

Authors:  Wobke E M van Dijk; Robert J J van Es; Maria E P Correa; Roger E G Schutgens; Karin P M van Galen
Journal:  TH Open       Date:  2021-09-09

8.  Efficacy and safety of Privigen(®) in patients with chronic inflammatory demyelinating polyneuropathy: results of a prospective, single-arm, open-label Phase III study (the PRIMA study).

Authors:  Jean-Marc Léger; Jan L De Bleecker; Claudia Sommer; Wim Robberecht; Mika Saarela; Jerzy Kamienowski; Zbigniew Stelmasiak; Orell Mielke; Björn Tackenberg; Amgad Shebl; Artur Bauhofer; Othmar Zenker; Ingemar S J Merkies
Journal:  J Peripher Nerv Syst       Date:  2013-06       Impact factor: 3.494

9.  Isoagglutinin reduction in intravenous immunoglobulin (IgPro10, Privigen) by specific immunoaffinity chromatography reduces its reporting rates of hemolytic reactions: an analysis of spontaneous adverse event reports.

Authors:  Amgad Shebl; Susie Gabriel; Kristy Van Dinther; Alphonse Hubsch; John-Philip Lawo; Liane Hoefferer; Susan Welsh
Journal:  Transfusion       Date:  2020-05-14       Impact factor: 3.157
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.